Abbott has opened a new pharmaceutical analytical research laboratory in Singapore’s Biopolis research park.
This new facility is Abbott’s first pharmaceutical research and development site in Southeast Asia. It will conduct stability studies, including studies on active pharmaceutical ingredients and novel formulations, to support global regulatory requirements for new pharmaceutical products, said the company.
Reportedly, the work done at the laboratory would enable Abbott to accelerate the development of innovative investigational medicines and potentially deliver new treatments to patients faster in areas such as neuroscience and cancer.
Abbott is also building a nutrition manufacturing plant in Singapore
John Leonard, senior vice president, Pharmaceuticals, Research and Development of Abbott, said: To realize the potential from the growth in Abbott’s early stage pipeline requires the resources of a truly global R&D organization and the scientific talent available in Singapore made it a logical choice for Abbott’s expansion in the region.
Yeoh Keat Chuan, executive director of Biomedical Sciences, Singapore Economic Development Board, said: We warmly welcome Abbott’s expansion into pharmaceutical R&D from its established base in Singapore, which includes nutritional manufacturing and regional headquarters. This project fits well with our intent for Singapore to be an international biomedical sciences research cluster advancing human health. From its new laboratory at the Biopolis, Abbott will be able to access the extensive network of public and private sector researchers, academics and clinicians nearby.”